Summit Therapeutics Share Discussion Threads

[hugus maximus] 06/2/2018 15:45

Tomorrow 7th Feb 5pm

"ACTION DUCHENNE WEBINAR 5 pm - reported positive interim data from Summit's PhaseOUT DMD ezutromid clinical trial.

In our continued aim to bring you up to the moment news from the international Duchenne community, Action Duchenne and Parent Project Muscular Dystrophy (PPMD) are co-moderating a Webinar to discuss Summit's recently reported positive interim 24-week data from PhaseOut DMD".

Register here for access to the Webinar

[chrisatrdg] 05/2/2018 19:14

Express Scripts drops Sarepta's Exondys 51 from preferred list:

[football] 05/2/2018 13:39

Probably more to do with the Dow futures being down over 300

But what if you spent all your money in the first half don't have any money for some Bovril and a pie

[freedosh] 05/2/2018 13:37

This is a game of 2 halves, football.
May buy summ more st the bottom.

[football] 05/2/2018 12:26

so the share price is now lower than when we got the good news rns about "24-Week Data From Phaseout Dmd" last week

wtf!

[waterloo01] 04/2/2018 14:17

The next big thing?
Sarepta Therapeutics (NASDAQ:SRPT) Exondys 51 is the only drug approved to treat Duchenne muscular dystrophy (DMD) in the U.S., and it can only be used in about 13% of DMD patients. New treatment options that can address everyone with DMD are needed, and Summit Therapeutics will find out later this year if it has a shot at doing that.

Summit Therapeutics is developing ezutromid, a drug that works differently from Exondys 51. While Exondys 51 skips mutations to boost production of dystrophin, a muscle-building protein, ezumtromid increases production of utrophin, another protein that has a similar muscle-building roll.

In healthy people, utrophin is produced in the early stages of muscle development, however, it shuts off as muscles mature and dystrophin takes over. Since DMD patients don't produce enough dystrophin, boosting utrophin production may slow disease progression.

Recently, the company presented 24-week interim phase 2 study results that were intriguing, and final results from its 48-week trial are expected in Q3 2018. At the 24-week mark, ezumtromid patients had increased utrophin expression and a reduction in muscle damage. If that data holds up, then regulators might consider awarding ezutromid an accelerated approval.

That could be a big win. Despite only being used to treat a small percentage of DMD patients and only being on the market a little over a year, Exondys 51's selling at an annualized pace north of $228 million. An eventual approval wouldn't be bad news to Sarepta Therapeutics, though. It licensed rights to ezutromid in 2016, so if it's successful, both it and Summit Therapeutics investors could be rewarded.

While ezutromid has the potential to be a nine-figure drug, investors might want to keep some of their optimism in check. After all, Exondys 51's approval was far from a lock, and it remains to be seen how regulators might view an increase utrophin production as a surrogate endpoint worthy of approval.

[clarkey26] 02/2/2018 17:33

So frustrating,basically nearly back where we started pre news!

[waterloo01] 31/1/2018 16:52

They have the same number of shares as last time. Difference is in percentage because of $12 raise I guess, which diluted them from just over to just under 26%

[football] 31/1/2018 16:47

SMMT / Summit Therapeutics plc / LANSDOWNE PARTNERS (UK) LLP - 3D/A (Activist Investment)

[hugus maximus] 30/1/2018 21:36

That was a solid day on the NASDAQ ... pushing to a $15 position before last few trades. Ending just down to around 14.50. Perhaps eventually we'll see a $16 position?

[chrisatrdg] 30/1/2018 19:43

Solid Biosciences slips on potential AAV toxicity



Edit: I note that Serepta currently down on NASDAQ & SMMT is up.

[waterloo01] 30/1/2018 08:00

To be published later today some improvement in incentives for developing antibiotics

[chrisatrdg] 29/1/2018 17:34

Ezutromid Reduces Muscle Damage in DMD Patients, Interim Data of Phase 2 Trial Shows:

[luminoso] 29/1/2018 15:26

I love the logic in that SA article. Sarepta are the best DMD bet because of their relationship with Summit and their cash pile with which to buy Summit,s drug ! Blinkers on or what ?

[dalcon01] 29/1/2018 13:26

DMD being discussed on Radio 2 at the moment

[hugus maximus] 29/1/2018 11:45

Edit addition: - "DMD competitor Summit Therapeutic's" ... I think this is how Sarepta investors view Summit on NASDAQ bulletin boards ... some bizarre conflicts pervade. (i.e. Sarepta's $60 million investment in Summit with a further $500 million in the pipeline, would suggest to me an "ally" ... highlighting the bizarre relationship)

Might the "runaway train" actually be a large van that's done done a bank job and still end up being caught by the cops before they leave city limits? I still have reservations about Sarepta's ongoing trials with eteplirsen and they present new data to the FDA again in 2019.

Perhaps with their $4 billion stash, they'll have changed getaway vehicle and be well away from the crime scene?

Doesn't their exon skipping pipeline rely on eteplirsen's proof of concept?

Whatever they're up to, success seems to be unquestionable. In addition, the answer to the question of their need for Summit's drug, if (as certainly seems to be the case) it cures even close to 100% of boys, it will be "UNDOUBTEDLY YES!"

[waterloo01] 29/1/2018 11:14

Summary
Summit's ezutromid shows positive interim data.

Solid's IPO looks a little risky.

Sarepta is a clear cut winner going forward.

Sarepta Therapeutics Inc. (SRPT) is the runaway train of DMD treatments that has plenty of upside left in 2018. DMD competitor Summit Therapeutic's (SMMT) recent positive results for its lead candidate ezutromid is a positive catalyst for Sarepta instead of a headwind. New DMD entrant Solid Biosciences LLC (SLDB) had a promising IPO surrounded by some drama, but seems a little expensive after its first day of trading. For exposure to the DMD space, go with the proven winner with lower risk and further lucrative upside in Sarepta Therapeutics.

Summit Therapeutics' ezutromid just announced positive interim results from a Phase 2 clinical trial in patients with Duchenne muscular dystrophy. The results included a meaningful reduction in muscle damage (23% decrease in myosin) along with an increase in utrophin protein intensity levels (7%) providing for the first evidence of engagement and proof of mechanism for the candidate. Ezutromid modulates utrophin, which has the potential to treat all boys and young men with DMD, compared to Sarepta's lead FDA approved drug Exondys 51, which is only for DMD patients amenable to exon 51 skipping. Sarepta has other candidates in its pipeline to address other DMD patients like the company's exon 53-skipping golodirsen, which might be get accelerated approval from the FDA in Q1 of 2018.

Sarepta was ahead of the curve by sealing an exclusive licensing and collaboration deal with Summit Therapeutics and its utrophin modulator pipeline featuring ezutromid in 2016. Sarepta's commercialization rights include Europe, Turkey and the Commonwealth of Independent States (Russia and eight former members of the Soviet bloc) with an additional option to the rights in Latin America. Sarepta and Summit will share utrophin modulator R&D costs starting in 2018 with a 45%/55% split with Sarepta giving Summit $40 million up front along with up to $522 million in milestones along with escalating royalties on net sales. Quite a deal between the two companies, which showcases the potential upside in revenues they see in Summit's utrophin pipeline.

One final note of interest between the two companies is Sarepta's giant cash horde after its recent capital raise, along with faster than expected sales of Exondys 51, compared to Summit's mediocre market cap. Sarepta recently raised $475 million late last year in a debt offering, its sitting on an additional $618.4 million in cash and equivalents according to its last conference call, and Exondys 51 is expected to bring in about $300 million in sales in 2018. Contrast this to Summit's current market cap, even after its recent ezutromid news release, sitting at a less than inspiring $217.31 million. I'm sure Sarepta is perfectly happy to grow its Exondys 51 sales as fast as humanly possible, with a good hedge against one of its main potential competitors in Summit, but, if the data continues to be promising, this relationship should bear watching.

[football] 29/1/2018 11:12

A bit of buying this morning 12o clock Rns

[chrisatrdg] 27/1/2018 20:40

Summit Therapeutics shares jump on 'exciting' interim results of ezutromid study

[chrisatrdg] 27/1/2018 20:34

SMALL CAP MOVERS: Summit Therapeutics is leading the fight to find a cure for Duchenne Muscular Dystrophy

[waterloo01] 27/1/2018 18:11

Summit Therapeutics spikes its phase 2 proof of concept in Duchenne
Company: Summit Therapeutics (SMMT)

Therapy: Ezutromid

Disease: Duchenne muscular dystrophy

News: SMMT announced findings from its phase 2 PhaseOUT DMD study, which is assessing the utrophin modulator ezutromid in patients with Duchenne musculuar dystrophy. These 24-week interim data showed a 23% mean reduction in a marker of muscle damage, with 14 of 22 patients receiving ezutromid achieving reduction of this marker. In addition, all patients remain ambulatory, and therapy was well tolerated.

Looking forward: This is an important finding for SMMT, as Duchenne muscular dystrophy remains a critical area of unmet need. A small molecule solution to slow disease progression might be a useful stopgap or a potential alternative as gene therapies continue to be researched, as well. Having more than one avenue for therapy is critical for helping to catch the patients who may not benefit from one strategy.

Overall, this is fantastic and surprising news from SMMT, and it should make you pay attention!

[chrisatrdg] 27/1/2018 15:46

bio-ceo-investor-conference
February 12 - 13, 2018 | New York Marriott Marquis
Summit are presenting on Monday, February 12th